|
A new surveillance method for tracking Lyme disease in the United States has led to a significant increase in reported cases in 2022, with over 62,000 cases reported to the CDC, nearly a 70% rise from the previous average. However, this spike is likely due to changes in surveillance methods rather than an actual increase in disease risk, according to the CDC. The revised reporting criteria, allowing high-incidence jurisdictions to report cases based solely on laboratory evidence, may capture more cases but also pose challenges for tracking historical trends.
|
The U.S. Food and Drug Administration (FDA) has approved Aurlumyn, manufactured by Eicos Sciences Inc, as the first medication to treat severe frostbite in adults, aiming to reduce the risk of finger or toe amputation. Frostbite, caused by skin and tissue damage due to cold temperatures, can lead to severe complications, including amputation, if untreated. Aurlumyn's active ingredient, iloprost, a vasodilator, facilitates blood flow and prevents clotting, demonstrating efficacy in preventing amputation in patients with severe frostbite during clinical trials. Common side effects of Aurlumyn include flushing, headache, nausea, vomiting, dizziness, heart palpitations, increased heart rate, and low blood pressure.
|
The FDA has expanded the use of Xolair, originally an asthma medication, to help individuals with food allergies avoid severe reactions caused by accidental exposure to allergenic foods. Xolair, administered via injections every two to four weeks, allows patients to tolerate higher amounts of allergenic foods without triggering major reactions, potentially transforming their quality of life.
|
A study published in Nature Medicine supports the FDA's assessment that medication abortion, conducted via telehealth appointments, is safe and effective, regardless of whether patients interact with providers via video or secure chat. The research, examining over 6,000 patients, found that 97.7% of medication abortions were effective and 99.7% were not followed by serious adverse events, reinforcing over 100 previous studies on mifepristone's safety and efficacy. As the Supreme Court prepares to hear a case about mifepristone's safety and FDA regulation, the study's findings could impact the ongoing legal debate surrounding medication abortion access.
|
A recent report from the US Centers for Disease Control and Prevention reveals a notable shift in drug overdose deaths, with smoking drugs surpassing injecting drugs as the primary route of drug use linked to fatal overdoses. Between 2020 and 2022, the percentage of overdose deaths associated with smoking drugs surged by almost 74%, reaching 23.1%, while deaths involving injections declined from 22.7% to 16.1%. The rise in smoking drugs, attributed to factors like perceived lower overdose risk and fewer adverse health effects compared to injecting, underscores the alarming impact of fentanyl, the primary driver behind the record-high drug overdose deaths seen in recent years.
|
|